Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Exclusion Criteria

• •1. Patients with pancreatic/ampullary carcinoma
• •2. Patients with mucous gallbladder carcinoma
• •3. Patients who had received radiotherapy or chemotherapy previously
• •4. Incomplete surgery recovery or biliary obstruction exist
• •5. Patients with radiographs confirmed distant metastases
• •6. Patients with prior or concurrent malignancy(excluded Cured basal cell carcinoma of the skin and Carcinoma in situ elsewhere)
• •7. Patients are allergy to macromolecular protein preparation(including anti-PD-1 antibody, uracil, cytosine pharmaceutical ingredients)
• •8. There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction
• •9. Patients had any active autoimmune disease or had experience of autoimmune disease.
• •10. Patients are receiving immunosuppressant and continue using within 2 weeks before enrollment
• •11. Patients with ascites or pleural effusion requiring therapeutic puncture or drainage
• •12. Patients with disease of the heart that are not well controlled
• •13. Abnormal coagulation(have tendency to bleed or receiving thrombolytic or anticoagulant therapy)
• •14. Patients had active infection or unexplained fever during screening and before first dose
• •15. Patients had abdominal fistula, gastrointestinal perforation, or abdominal abscess less than 4 weeks before first dose.
• •16. Patients past or present with pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severely impaired lung function, etc
• •17. Patients have congenital or acquired immune deficiency; Hepatitis B patients: HBV DNA≥10\^3/ml, Hepatitis C patients: HCV RNA≥10\^3/ml, Chronic hepatitis B virus carriers: HBV DNA\<2000 IU/ml（\<10\^4 copies/ml), patients must receive antiviral therapy during the trial
• •18. Patients are participating in other relevant clinical studies or it has been less than 1 month since the end of the previous clinical study; Patients maybe receive other systemic antitumor therapy during the study period;
• •19. Patients received live vaccination less than 4 weeks before administration or possibly receive during the study period.
• •20. Patients had history of psychotropic substance abuse, alcohol abuse, or drug abuse.
• •21. Patients cannot or does not agree to pay the cost of examination and treatment expense
• •22. The researchers concluded the patients should be excluded from this study